Ascendis Pharma A (ASND) EBITDA Margin (2014 - 2026)
Ascendis Pharma A's (ASND) quarterly EBITDA Margin came in at 256.45% in Q1 2026, up 35025.0% year-on-year from N/an in Q1 2025, and up 8367.65% quarter-over-quarter from 3.03% in Q4 2025.
Ascendis Pharma A (ASND) EBITDA Margin (2014 - 2026) Analysis & Trends
Ascendis Pharma A has disclosed EBITDA Margin across 13 years of filings, most recently posting 256.45% for Q1 2026.
- EBITDA Margin for Q1 2026 came in at 256.45%, up 35025.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 57.68% (down 8545461.0% YoY), and the FY2025 annual result was 18.92%, up 4978.0% from the prior year.
- EBITDA Margin came in at 256.45% for Q1 2026 at Ascendis Pharma A, up from 3.03% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 151717.42% in Q4 2024 to a low of 1831.77% in Q1 2022.
- The 5-year median for EBITDA Margin is 171.26% (2024), against an average of 8549.81%.
- Across the five-year window, EBITDA Margin surged 15173248 bps in 2024 and sank 15171439 bps in 2025, its largest moves.
- Ascendis Pharma A's EBITDA Margin stood at 643.75% in 2022, then surged by 98 bps to 15.07% in 2023, then jumped by 1007137 bps to 151717.42% in 2024, then slumped by 100 bps to 3.03% in 2025, then surged by 8368 bps to 256.45% in 2026.
- The last three EBITDA Margin figures came in at 256.45% (Q1 2026), 3.03% (Q4 2025), and 29.29% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ascendis Pharma A | 2.75 Bn | 2.08 Bn | 268.20 Mn | 256.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 256.45% |
| Dec 31, 2025 | 3.03% |
| Sep 30, 2025 | -29.29% |
| Jun 30, 2025 | -25.47% |
| Mar 31, 2025 | -93.81% |
| Dec 31, 2024 | 151,717.42% |
| Sep 30, 2024 | -171.26% |
| Jun 30, 2024 | -303.81% |
| Mar 31, 2024 | -136.58% |
| Dec 31, 2023 | -15.07% |
| Sep 30, 2023 | -336.54% |
| Jun 30, 2023 | -258.37% |
| Mar 31, 2023 | -332.55% |
| Dec 31, 2022 | -643.75% |
| Sep 30, 2022 | -1,119.44% |
| Jun 30, 2022 | -1,332.40% |
| Mar 31, 2022 | -1,831.77% |
| Dec 31, 2021 | -145.12% |
| Sep 30, 2021 | -7,127.76% |
| Jun 30, 2021 | -13,140.61% |